Regulation of RAGE for Attenuating Progression of Diabetic Vascular Complications
Open Access
- 29 October 2011
- journal article
- review article
- Published by Wiley in Experimental Diabetes Research
- Vol. 2012, 1-8
Abstract
Diabetic angiopathy including micro- and macroangiopathy is concerned with high rate of morbidity and mortality in patients with long-standing diabetes. Receptor for advanced glycation end products (RAGE) and its ligands have been considered as important pathogenic triggers for the progression of the vascular injuries in diabetes. The deleterious link between RAGE and diabetic angiopathy has been demonstrated in animal studies. Preventive and therapeutic strategies focusing on RAGE and its ligand axis may be of great importance in relieving diabetic vascular complications and reducing the burden of disease.Keywords
This publication has 92 references indexed in Scilit:
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetesClinical Science, 2010
- Blockade of Endothelial-Mesenchymal Transition by a Smad3 Inhibitor Delays the Early Development of Streptozotocin-Induced Diabetic NephropathyDiabetes, 2010
- Deletion of the Receptor for Advanced Glycation End Products Reduces Glomerulosclerosis and Preserves Renal Function in the Diabetic OVE26 MouseDiabetes, 2010
- Advanced Glycation End-Product of Low Density Lipoprotein Activates the Toll-Like 4 Receptor Pathway Implications for Diabetic AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42Journal of Biological Chemistry, 2008
- Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stressBiochemical Society Transactions, 2008
- Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in DiabetesDiabetes, 2008
- Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross‐links, on the cardiovascular system of diabetic ratsBritish Journal of Pharmacology, 2007
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996